Current development of a lipid-based nanocochleates containing Amphotericin B for oral administration

Changxue Ji,Zeliang Qiu,Zhiwen Yang,Ping Luo
DOI: https://doi.org/10.1016/j.jddst.2024.105347
IF: 5
2024-01-06
Journal of Drug Delivery Science and Technology
Abstract:Amphotericin B (AmB) is still the most common antifungal medication in the treatment of systemic fungal infections. Generally, AmB is restricted to intravenous administration in the medical application, accompanied by dose-dependent severe nephrotoxicity, hepatotoxicity, allergic shock, and so on To date, various drug delivery vehicles have been designed to develop the oral formulation of AmB. Importantly, AmB-loaded nanocochleate is an interesting formulation that has entered clinical trial, showing a favorable clinical outcome upon oral administration. Thus, this review summarizes the recent advances in the oral preclinical and clinical trials of AmB-loaded nanocochleates. Graphical abstract Download : Download high-res image (191KB) Download : Download full-size image
pharmacology & pharmacy
What problem does this paper attempt to address?